A nationwide U.S. study published in JAMA, analyzing data from 2.15 million women with breast cancer, found that choosing complementary and alternative medicine (CAM) instead of evidence-based therapy ...

Healthcare is entering a new digital era. Yet existing systems still rely on fragmented data and outdated software that struggle to support truly patient-centered care. Real progress now depends on ...

I am a software developer and a 4th-year Computer Engineering student at the Turkish-German University. I have worked on numerous software projects, especially those related to healthcare. My primary ...

Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved a 51% overall response rate in RAS/BRAF wild-type metastatic colorectal ...

Researchers at the Johns Hopkins KCC have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of patients previously lacking precision options. The ...

The Phase 3 EV-304 KEYNOTE-B15 trial showed that perioperative enfortumab vedotin (PADCEV) plus pembrolizumab (Keytruda) significantly improved event-free survival and overall survival versus ...

The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated NSCLC, enabling five-minute administration with fewer infusion reactions. In Phase III PALOMA-3, ...

Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab regimen increased objective response rates from 37% to 49%, tripled median ...

FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive prostate cancer (mCSPC), following results from the Phase 3 AMPLITUDE ...

An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...

Preoperative radiation boosted antitumor immunity and treatment response in HR positive, HER2 negative breast cancer in the phase II P RAD trial presented at SABCS 2025. When combined with ...